Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. This damage allows bacteria and mucus to build up in the lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss, and fever.
The Bronchiectasis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchiectasis (Respiratory) and features dormant and discontinued projects.
Bronchiectasis Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Bronchiectasis pipeline drugs market are Dipeptidyl Peptidase 1, 30S Ribosomal Subunit, Neutrophil Elastase, 16S Ribosomal RNA, Alpha 1 Antitrypsin, Bacterial Cell Membrane, Cathelicidin Antimicrobial Peptide, Cystic Fibrosis Transmembrane Conductance Regulator, Cystine, and Gelsolin.
Bronchiectasis Pipeline Drugs Market Analysis, by Targets
For more Bronchiectasis pipeline drugs market target insights, download a free report sample
Bronchiectasis Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanisms of action of the Bronchiectasis pipeline drugs market are Dipeptidyl Peptidase 1 Inhibitor, 30S Ribosomal Subunit Inhibitor, Neutrophil Elastase Inhibitor, 16S Ribosomal RNA Inhibitor, Alpha 1 Antitrypsin Replacement, Bacterial Cell Membrane Disruptor, Cathelicidin Antimicrobial Peptide Activator, Cystic Fibrosis Transmembrane Conductance Regulator Activator, Cystine Depletor, and Gelsolin Replacement.
Bronchiectasis Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the Bronchiectasis pipeline drugs market, download a free report sample
Bronchiectasis Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Bronchiectasis pipeline drugs market are inhalational, oral, intravenous, intradermal, intrapulmonary, parenteral, and subcutaneous.
Bronchiectasis Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Bronchiectasis pipeline drugs market, download a free report sample
Bronchiectasis Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Bronchiectasis pipeline drugs market are Small Molecule, Biologic, Cell Therapy, Recombinant Protein, Synthetic Peptide, Antibody, Blood Derivative, Gene-Modified Cell Therapy, and Monoclonal Antibody.
Bronchiectasis Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Bronchiectasis pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the Bronchiectasis pipeline drugs market are Suzhou Regend Therapeutics Co Ltd, Armata Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, Zambon Co SpA, BioAegis Therapeutics Inc, Chiesi Farmaceutici SpA, Cila Therapeutics, CSL Ltd, Destiny Pharma Plc, and Haisco Pharmaceutical Group Co Ltd.
Bronchiectasis Pipeline Drugs Market Analysis, by Companies
To know more about the Bronchiectasis pipeline drugs market companies, download a free report sample
Bronchiectasis Pipeline Drugs Market Report Overview
Key Targets | Dipeptidyl Peptidase 1, 30S Ribosomal Subunit, Neutrophil Elastase, 16S Ribosomal RNA, Alpha 1 Antitrypsin, Bacterial Cell Membrane, Cathelicidin Antimicrobial Peptide, Cystic Fibrosis Transmembrane Conductance Regulator, Cystine, and Gelsolin |
Key Mechanism of Actions | Dipeptidyl Peptidase 1 Inhibitor, 30S Ribosomal Subunit Inhibitor, Neutrophil Elastase Inhibitor, 16S Ribosomal RNA Inhibitor, Alpha 1 Antitrypsin Replacement, Bacterial Cell Membrane Disruptor, Cathelicidin Antimicrobial Peptide Activator, Cystic Fibrosis Transmembrane Conductance Regulator Activator, Cystine Depletor, and Gelsolin Replacement |
Key Routes of Administration | Inhalational, Oral, Intravenous, Intradermal, Intrapulmonary, Parenteral, and Subcutaneous |
Key Molecule Types | Small Molecule, Biologic, Cell Therapy, Recombinant Protein, Synthetic Peptide, Antibody, Blood Derivative, Gene-Modified Cell Therapy, and Monoclonal Antibody |
Key Companies | Suzhou Regend Therapeutics Co Ltd, Armata Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, Zambon Co SpA, BioAegis Therapeutics Inc, Chiesi Farmaceutici SpA, Cila Therapeutics, CSL Ltd, Destiny Pharma Plc, and Haisco Pharmaceutical Group Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
- Reviews of pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
- Evaluation of Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Bronchiectasis (Respiratory).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with the potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
BioAegis Therapeutics Inc
Boehringer Ingelheim International GmbH
Chiesi Farmaceutici SpA
Cila Therapeutics
CSL Ltd
Destiny Pharma Plc
Haisco Pharmaceutical Group Co Ltd
Helperby Therapeutics Group Ltd
Insmed Inc
Joincare Pharmaceutical Group Industry Co Ltd
Kamada Pharmaceuticals
Kyowa Kirin Co Ltd
MDI Therapeutics Inc
Metagone Biotech Inc
Novabiotics Ltd
Novartis AG
OrPro Therapeutics Inc
Parion Sciences Inc
PureIMS BV
Renovion Inc
Santhera Pharmaceuticals Holding AG
SolAeroMed Inc
Spexis AG
Suzhou Regend Therapeutics Co Ltd
Therapeutic Systems Research Laboratories Inc
Thirty Respiratory Ltd
Vast Therapeutics Inc
Zambon Co SpA
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Bronchiectasis pipeline drugs market?
Some of the key targets of the Bronchiectasis pipeline drugs market are Dipeptidyl Peptidase 1, 30S Ribosomal Subunit, Neutrophil Elastase, 16S Ribosomal RNA, Alpha 1 Antitrypsin, Bacterial Cell Membrane, Cathelicidin Antimicrobial Peptide, Cystic Fibrosis Transmembrane Conductance Regulator, Cystine, and Gelsolin.
-
What are the key mechanisms of action in the Bronchiectasis pipeline drugs market?
Some of the key mechanisms of action in the Bronchiectasis pipeline drugs market are Dipeptidyl Peptidase 1 Inhibitor, 30S Ribosomal Subunit Inhibitor, Neutrophil Elastase Inhibitor, 16S Ribosomal RNA Inhibitor, Alpha 1 Antitrypsin Replacement, Bacterial Cell Membrane Disruptor, Cathelicidin Antimicrobial Peptide Activator, Cystic Fibrosis Transmembrane Conductance Regulator Activator, Cystine Depletor, and Gelsolin Replacement.
-
What are the key routes of administration in the Bronchiectasis pipeline drugs market?
The key routes of administration in the bronchiectasis pipeline drugs market are inhalational, oral, intravenous, intradermal, intrapulmonary, parenteral, and subcutaneous.
-
What are the key molecule types in the Bronchiectasis pipeline drugs market?
The molecule types in the Bronchiectasis pipeline drugs market are Small Molecule, Biologic, Cell Therapy, Recombinant Protein, Synthetic Peptide, Antibody, Blood Derivative, Gene-Modified Cell Therapy, and Monoclonal Antibody.
-
Which are the key companies in the Bronchiectasis pipeline drugs market?
Some of the key companies in the Bronchiectasis pipeline drugs market are Suzhou Regend Therapeutics Co Ltd, Armata Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, Zambon Co SpA, BioAegis Therapeutics Inc, Chiesi Farmaceutici SpA, Cila Therapeutics, CSL Ltd, Destiny Pharma Plc, and Haisco Pharmaceutical Group Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.